Literature DB >> 10611242

Inhibition of TATA-binding protein function by SAGA subunits Spt3 and Spt8 at Gcn4-activated promoters.

R Belotserkovskaya1, D E Sterner, M Deng, M H Sayre, P M Lieberman, S L Berger.   

Abstract

SAGA is a 1.8-MDa yeast protein complex that is composed of several distinct classes of transcription-related factors, including the adaptor/acetyltransferase Gcn5, Spt proteins, and a subset of TBP-associated factors. Our results indicate that mutations that completely disrupt SAGA (deletions of SPT7 or SPT20) strongly reduce transcriptional activation at the HIS3 and TRP3 genes and that Gcn5 is required for normal HIS3 transcriptional start site selection. Surprisingly, mutations in Spt proteins involved in the SAGA-TBP interaction (Spt3 and Spt8) cause derepression of HIS3 and TRP3 transcription in the uninduced state. Consistent with this finding, wild-type SAGA inhibits TBP binding to the HIS3 promoter in vitro, while SAGA lacking Spt3 or Spt8 is not inhibitory. We detected two distinct forms of SAGA in cell extracts and, strikingly, one lacks Spt8. Conditions that induce HIS3 and TRP3 transcription result in an altered balance between these complexes strongly in favor of the form without Spt8. These results suggest that the composition of SAGA may be dynamic in vivo and may be regulated through dissociable inhibitory subunits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10611242      PMCID: PMC85153          DOI: 10.1128/MCB.20.2.634-647.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  65 in total

1.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

Review 2.  Mechanisms of transcriptional activation in vivo: two steps forward.

Authors:  L A Stargell; K Struhl
Journal:  Trends Genet       Date:  1996-08       Impact factor: 11.639

3.  The CBP co-activator is a histone acetyltransferase.

Authors:  A J Bannister; T Kouzarides
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

4.  A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains.

Authors:  A Goppelt; G Stelzer; F Lottspeich; M Meisterernst
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

5.  Essential functional interactions of SAGA, a Saccharomyces cerevisiae complex of Spt, Ada, and Gcn5 proteins, with the Snf/Swi and Srb/mediator complexes.

Authors:  S M Roberts; F Winston
Journal:  Genetics       Date:  1997-10       Impact factor: 4.562

6.  ADR1 activation domains contact the histone acetyltransferase GCN5 and the core transcriptional factor TFIIB.

Authors:  Y C Chiang; P Komarnitsky; D Chase; C L Denis
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

7.  The NOT, SPT3, and MOT1 genes functionally interact to regulate transcription at core promoters.

Authors:  M A Collart
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

Review 8.  Biochemistry and structural biology of transcription factor IID (TFIID).

Authors:  S K Burley; R G Roeder
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

9.  Absolute mRNA levels and transcriptional initiation rates in Saccharomyces cerevisiae.

Authors:  V Iyer; K Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.

Authors:  X J Yang; V V Ogryzko; J Nishikawa; B H Howard; Y Nakatani
Journal:  Nature       Date:  1996-07-25       Impact factor: 49.962

View more
  80 in total

1.  The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis.

Authors:  J Park; S Kunjibettu; S B McMahon; M D Cole
Journal:  Genes Dev       Date:  2001-07-01       Impact factor: 11.361

2.  p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction.

Authors:  J Xing; H M Sheppard; S I Corneillie; X Liu
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  Components of the SAGA histone acetyltransferase complex are required for repressed transcription of ARG1 in rich medium.

Authors:  Andrea R Ricci; Julie Genereaux; Christopher J Brandl
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 4.  Gcn4p, a master regulator of gene expression, is controlled at multiple levels by diverse signals of starvation and stress.

Authors:  Alan G Hinnebusch; Krishnamurthy Natarajan
Journal:  Eukaryot Cell       Date:  2002-02

5.  Differential requirement of SAGA components for recruitment of TATA-box-binding protein to promoters in vivo.

Authors:  Sukesh R Bhaumik; Michael R Green
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

Review 6.  Acetylation of histones and transcription-related factors.

Authors:  D E Sterner; S L Berger
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

Review 7.  Multi-protein complexes in eukaryotic gene transcription.

Authors:  Ernest Martinez
Journal:  Plant Mol Biol       Date:  2002-12       Impact factor: 4.076

8.  Positive and negative functions of the SAGA complex mediated through interaction of Spt8 with TBP and the N-terminal domain of TFIIA.

Authors:  Linda Warfield; Jeffrey A Ranish; Steven Hahn
Journal:  Genes Dev       Date:  2004-05-01       Impact factor: 11.361

9.  Molecular requirements for gene expression mediated by targeted histone acetyltransferases.

Authors:  Sandra Jacobson; Lorraine Pillus
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 10.  ATAC-king the complexity of SAGA during evolution.

Authors:  Gianpiero Spedale; H Th Marc Timmers; W W M Pim Pijnappel
Journal:  Genes Dev       Date:  2012-03-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.